Merck & Co., Inc. (MRK) Stock News
Follow the latest Merck & Co., Inc. (MRK) news and market headlines alongside the live MRK price. Stay informed on what's moving MRK.
News
Read Full Article - Read Full Article
FDA Reportedly Shelves Fast-Track Drug Review Pilot Program During Leadership Vacuum: Report
The FDA reportedly shelves its fast-track drug voucher pilot amid internal chaos, returning review oversight to career scientists.
- Read Full Article
MRNA Stock Up 3% Since Q3 Earnings Release: How to Play the Stock?
Moderna shares gained 3% following better-than-expected Q3 2026 earnings and raised full-year revenue guidance to 15-25% growth, driven by stronger international COVID-19 vaccine sales. The company's oncology pipeline, particularly its personalized cancer therapy intismeran developed with Merck, showed promising phase III results with a 42% reduction in recurrence or death risk. Despite premium valuation and ongoing cash burn concerns, Moderna maintains a Zacks Rank #2 (Buy) rating, supported by expanding respiratory vaccine portfolio and oncology opportunities.
- Read Full Article
Can Gilead Sciences' HIV Business Fuel Sustainable Long-Term Growth?
Gilead Sciences reported strong momentum in its HIV business, with flagship drug Biktarvy commanding 53% U.S. market share and injectable PrEP therapy Yeztugo emerging as a key growth driver with $305 million in quarterly sales. The company raised its 2026 HIV sales growth outlook to 12%, supported by strong performances from Biktarvy, Descovy, and Yeztugo. However, aggressive dealmaking and integration costs are pressuring near-term profitability.
- Read Full Article
Moderna Analyst Day: Details Strategic Shift Toward Oncology and Enhanced Production Capabilities
Moderna raises its 2026 revenue forecast to 15%-25% and accelerates oncology investments, expanding its mRNA platform into new therapies.
- Read Full Article
Can LLY's Expanding Obesity Pipeline Sustain Its GLP-1 Leadership?
Eli Lilly has established itself as a dominant player in the obesity treatment market, with Mounjaro and Zepbound generating 65% of revenues. The company's April 2026 launch of Foundayo (oral GLP-1) recorded $281 million in sales, offering a more convenient alternative to injectable treatments. Lilly is developing next-generation therapies including retatrutide (triple-acting), eloralintide, and EloraTZP to maintain market leadership. However, competition is intensifying from Novo Nordisk and emerging biotech companies.
Explore More US Stocks
Data Sources and Disclosures
News and data on this page is provided by our partnered third-party news and market data provider, with the original publisher credited on each article. All third-party content reflects the views of the original publisher and does not represent the views of MEXC. Price and market data shown on this page are provided by third-party data providers and may be delayed. MEXC offers trading products related to MRK, including RealStocks and Stock Futures.
Disclaimer
The content on this page is provided for informational purposes only and does not constitute investment, financial, or trading advice. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of any news or market data shown. Trading U.S. stocks and related products involves significant risk, and prices can move sharply in a short period. Past performance does not guarantee future results. Please conduct your own research and assess your financial situation and risk tolerance before making any investment decisions. MEXC is not liable for any losses arising from the use of this information.


